Drug Trial Radar · NCT05634811
Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,547
Actual
Start
Dec 12, 2022
Primary completion
Jul 21, 2025
Study completion Jul 21, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: * are healthy * are age 5 through 17 * have not been diagnosed with any form of Lyme disease in the past * have not received any vaccines for Lyme disease in the past Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group. Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo. Everyone participating in this study will: * get the shots in a clinic or in a hospital office * receive a total of 4 shots * receive the first 3 shots within 6 months * receive the last shot about 1 year afterwards * need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose.
Conditions
- Lyme Disease
Interventions
VLA15Biological
6-valent OspA-based Lyme disease vaccine
Normal SalineOther
0.9% sodium chloride solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
- Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
- Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
- Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
- Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study VaccinationTime frame: From Day 1 through Day 7 after any study vaccination
- Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
- Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
- Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
- Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
- Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study VaccinationTime frame: From Day 1 through Day 7 after any study vaccination
- Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1Time frame: From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)
- Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2Time frame: From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)
- Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3Time frame: From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)
- Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)
- Percentage of Participants With AEs Through 1 Month Following Any Study VaccinationTime frame: From Day 1 through 1 Month after any study vaccination
- Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the StudyTime frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
- Percentage of Participants With Serious Adverse Events (SAEs) Throughout the StudyTime frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
Locations
65 sites in 1 country. Site status is shown where the registry gives one.
UAB Child Health Research Unit (CHRU)
Birmingham, Alabama
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama
Lakeview Clinical Research
Guntersville, Alabama
Coast Clinical Research, LLC
Bellflower, California
Apex Research Group LLC
Fair Oaks, California
New England Research Associates
Bridgeport, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
Bio-Medical Research LLC
Miami, Florida
GCP Research, Global Clinical professionals
St. Petersburg, Florida
MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research
Tampa, Florida
ForCare Clinical Research
Tampa, Florida
Tekton Research, LLC.
Chamblee, Georgia
ASR, LLC
Boise, Idaho
Clinical Research Prime
Idaho Falls, Idaho
Clinical Research Prime Rexburg
Rexburg, Idaho
University of Chicago Medical Center
Chicago, Illinois
AMR Clinical
El Dorado, Kansas
AMR Clinical
Wichita, Kansas
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky
All Children Pediatrics
Louisville, Kentucky
MD Medical Research
Oxon Hill, Maryland
White Oak Pediatrics
Silver Spring, Maryland
Sisu BHR
Springfield, Massachusetts
Michigan Center of Medical Research (MICHMER)
Bingham Farms, Michigan
Vida Clinical Studies, LLC
Dearborn Heights, Michigan
Great Lakes Research Institute
Southfield, Michigan
Clinical Research Institute
Minneapolis, Minnesota
Velocity Clinical Research, Omaha
Omaha, Nebraska
Hassman Research Institute
Marlton, New Jersey
Rutgers University
New Brunswick, New Jersey
IMA Clinical Research Warren
Warren Township, New Jersey
Velocity Clinical Research, Binghamton
Binghamton, New York
Buffalo Clinical and Translational Research Center
Buffalo, New York
Advanced Specialty Care
Commack, New York
Smith Allergy and Asthma Specialists
Cortland, New York
Stony Brook Medicine Clinical Research Center
East Setauket, New York
Upstate Global Health Institute
East Syracuse, New York
Southampton Hospital
Hampton Bays, New York
Smith Allergy & Asthma Specialists
Horseheads, New York
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.